<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04833231</url>
  </required_header>
  <id_info>
    <org_study_id>omurilban1</org_study_id>
    <nct_id>NCT04833231</nct_id>
  </id_info>
  <brief_title>The Relationship Between Renal Functions and Multi Drug Resistant Organisms</brief_title>
  <official_title>The Relationship Between Renal Functions and Multi Drug Resistant Organisms in Patients With Ventilator Associated Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konya Numune Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Konya Numune Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ventilator-associated pneumonia (VAP) is the most common nosocomial infection in patients&#xD;
      receiving invasive mechanical ventilation (MV). Antibiotic resistance poses an increasing&#xD;
      threat due to the rise of infections caused by multidrug-resistant organisms (MDROs).Despite&#xD;
      the increase in the frequency of MDRO colonisation and infection in dialysis patients, it is&#xD;
      not known enough whether the risk of multi-drug resistant (MDR) pneumonia increases in&#xD;
      mild-to-severe chronic kidney disease (CKD) (eGFR &lt;60 mL/min/1.73 m2) patients not receiving&#xD;
      dialysis. Therefore, in our study, the investigators aimed to evaluate the relationship&#xD;
      between renal functions and MDR VAP risk and the specific microbial pattern.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study was performed on adult patients intubated and receiving&#xD;
      MV for at least 48 hours in the 42-bed surgical and medical Intensive Care Unit. The study&#xD;
      was conducted between August 2019 and January 2021 and approved by the Ethics Committee of&#xD;
      Necmettin Erbakan University Medical School. Informed consents were obtained from patients&#xD;
      participating in the study or from their relatives. The characteristics of patients with MDRO&#xD;
      infection associated with different eGFR categories in VAP patients were recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">January 31, 2021</completion_date>
  <primary_completion_date type="Actual">January 15, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>18 Months</target_duration>
  <primary_outcome>
    <measure>Multi-drug resistant (MDR) pneumonia</measure>
    <time_frame>18 months</time_frame>
    <description>The presence of an infection with a resistant pathogen in patients with impaired renal function (eGFR &lt;60 mL/min/1.73 m2) served as our primary outcome measure</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">133</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Glomerular Filtration Rate</condition>
  <condition>Drug Resistance</condition>
  <arm_group>
    <arm_group_label>High eGFR group (eGFR ≥60 mL/ min/1.73 m2)</arm_group_label>
    <description>Patients with estimated glomerular filtration rate (eGFR) ≥60 mL/ min/1.73 m2 as high eGFR group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low eGFR group (eGFR &lt;60 mL/min/1.73 m2)</arm_group_label>
    <description>Patients with estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m2 as low eGFR group</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients who were intubated endotracheally and received mechanical ventilation&#xD;
        treatment for at least 48 hours in ICU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of 18 years of age and above&#xD;
&#xD;
          -  A clinical suspicion of VAP as defined in the American Thoracic Society (ATS)&#xD;
             guidelines&#xD;
&#xD;
          -  A Clinical Pulmonary Infection Score (CPIS) &gt; 6&#xD;
&#xD;
          -  No signs and symptoms of infection at the time of admission to the ICU&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute kidney injury&#xD;
&#xD;
          -  Renal replacement treatment (RRT)&#xD;
&#xD;
          -  Dialysis&#xD;
&#xD;
          -  Renal transplantation&#xD;
&#xD;
          -  Active tuberculosis&#xD;
&#xD;
          -  Malnutrition&#xD;
&#xD;
          -  Immunosuppression (neutropenia, HIV positivity, transplantation, prednisone treatment&#xD;
             of ≥20 mg/day, etc.)&#xD;
&#xD;
          -  Any extrapulmonary infection other than VAP at the time of being included in the study&#xD;
&#xD;
          -  Respiratory cultures presented fungal agents&#xD;
&#xD;
          -  Normal flora&#xD;
&#xD;
          -  No growth&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Omur ILBAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konya Numune Hospital, Department of Intensive Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konya Numune Hospital</name>
      <address>
        <city>Konya</city>
        <zip>42060</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2021</study_first_posted>
  <last_update_submitted>April 3, 2021</last_update_submitted>
  <last_update_submitted_qc>April 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konya Numune Hospital</investigator_affiliation>
    <investigator_full_name>Omur ILBAN</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

